KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Frequently asked questions
What sector does Kala Pharmaceuticals, Inc (KALA) operate in?
Kala Pharmaceuticals, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Kala Pharmaceuticals, Inc (KALA) current stock price?
As of the latest data, Kala Pharmaceuticals, Inc stock price is $0.95, with a previous close of $0.92. Kala Pharmaceuticals, Inc gained $0.02 in the last trading session, representing a 2.38% increase.
What is Kala Pharmaceuticals, Inc (KALA) current market capitalization?
Kala Pharmaceuticals, Inc market cap is approximately 18.30 million.
What is Kala Pharmaceuticals, Inc (KALA) Earnings Per Share (EPS)?
The trailing EPS is -$102.01, and the forward EPS is -$0.53.
What is Kala Pharmaceuticals, Inc (KALA) EBITDA?
Kala Pharmaceuticals, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.62 million.
Does Kala Pharmaceuticals, Inc (KALA) pay dividends?
No. Kala Pharmaceuticals, Inc does not pay a dividend.
What is Kala Pharmaceuticals, Inc (KALA) beta (volatility) score?
Kala Pharmaceuticals, Inc has a beta of -2.281, indicating lower volatility than the overall market.
